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Recent concerns over the impact of antidepressant medications, including the selective
serotonin reuptake inhibitors (SSRIs), on cardiovascular function highlight the importance
of research on the moderating effects of specific lifestyle factors such as physical activity.
Studies in affective neuroscience have demonstrated robust acute effects of SSRIs, yet
the impact of SSRIs on cardiovascular stress responses and the moderating effects of
physical activity remain to be determined. This was the goal of the present study, which
involved a double-blind, randomized, placebo-controlled, cross-over trial of a single-dose
of escitalopram (20mg) in 44 healthy females; outcomes were heart rate (HR) and its
variability. Participants engaging in at least 30min of vigorous physical activity at least
3 times per week (regular exercisers) showed a more resilient cardiovascular stress
response than irregular vigorous exercisers, a finding associated with a moderate effect
size (Cohen’s d = 0.48). Escitalopram attenuated the cardiovascular stress response
in irregular exercisers only (HR decreased: Cohen’s d = 0.80; HR variability increased:
Cohen’s d = 0.33). HR during stress under escitalopram in the irregular exercisers was
similar to that during stress under placebo in regular exercisers. These findings highlight
that the effects of regular vigorous exercise during stress are comparable to the effects
of an acute dose of escitalopram, highlighting the beneficial effects of this particular
antidepressant in irregular exercisers. Given that antidepressant drugs alone do not seem
to protect patients from cardiovascular disease (CVD), longitudinal studies are needed to
evaluate the impact of exercise on cardiovascular stress responses in patients receiving
long-term antidepressant treatment.
Keywords: selective serotonin reuptake inhibitors (SSRIs), escitalopram, exercise, physical activity, cardiovascular
stress response, heart rate, heart rate variability, HRV
INTRODUCTION
Depression and cardiovascular disease (CVD) are leading bur-
dens of disease and this burden is projected to worsen up to
2030 and beyond with ageing of the population and increas-
ing prevalence of multi-morbidity (Mathers and Loncar, 2006;
Langan et al., 2013). Critically, depression increases risk for the
development of CVD 1.5-fold, while patients with CVD and
depression have a 2- to 3-fold increased risk of future cardiac
events compared to those cardiac patients who do not have
depression (Rudisch and Nemeroff, 2003). Psychological stress
plays a key role in the development of depression (Cohen et al.,
2007), and increases risk of mortality from a number of causes
including CVD, cancer and external causes over an 8 year follow-
up period (Russ et al., 2012). While many biological factors,
including the hypothalamic-pituitary-adrenal (HPA) axis dys-
function and altered inflammatory processes, contribute to the
relationship between stress, psychiatric illness and CVD, vagally
mediated cardiovascular function—indexed by increases in heart
rate (HR) and decreases in heart rate variability (HRV)—may
underlie a substantial part of this risk (Thayer et al., 2010a;
Nemeroff and Goldschmidt-Clermont, 2012). Importantly, the
inhibitory function of the vagus nerve regulates both the HPA axis
and inflammatory processes (Tracey, 2002; Thayer and Sternberg,
2006; Huston and Tracey, 2010; Kemp and Quintana, 2013), lead-
ing to proposals that chronic impairment in vagal function is
an early marker of future morbidity and mortality (Kemp et al.,
2010; Thayer et al., 2010b; Åberg et al., 2013; Kemp andQuintana,
2013).
Acute psychological stress is associated with parasympathetic
withdrawal, sympathetic activation, an increase in HR and reduc-
tions in its variability (Madden and Savard, 1995; Porges, 1995;
Steptoe and Kivimäki, 2012), while chronic stress is associated
with persistent cardiovascular stress responses, which may then
contribute to psychiatric illness, physical ill-health and all-cause
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mortality (Thayer and Brosschot, 2005; Thayer et al., 2010b;
Lemogne et al., 2011; Åberg et al., 2013; Kemp and Quintana,
2013). Epidemiological research has even demonstrated that an
increased resting HR increases the risk of suicide by 19–37% over
a follow-up period of 9 years even after accounting for covari-
ates including depressed mood (Lemogne et al., 2011). In another
study lower cardiovascular fitness determined using the cycle
ergonometric test at 18 years of age predicts an increased risk
of suicide attempt and death by suicide over a follow-up period
of 42 years (Åberg et al., 2013). As lower cardiovascular fitness is
associated with increasedHR and reducedHR variability (Rennie,
2003), these findings highlight an important role of vagally medi-
ated cardiovascular function in regards to psychological wellbeing
as well as physical health. Importantly, increased parasympa-
thetic control is associated with positive emotions (Kok and
Fredrickson, 2010), resilience (Kashdan and Rottenberg, 2010)
and improved regulation over the HPA axis and inflammatory
processes (Tracey, 2002; Thayer and Sternberg, 2006; Huston
and Tracey, 2010; Kemp and Quintana, 2013), thereby con-
tributing to psychological wellbeing and physical health. National
guidelines (Australian Government Department of Health and
Ageing: http://www.health.gov.au/internet/main/publishing.nsf/
content/health-pubhlth-strateg-phys-act-guidelines) distinguish
between regular moderate-intensity physical activity and regu-
lar vigorous exercise, recommending at least 30min of vigorous
exercise on top of regular activity for health and fitness benefits.
The selective serotonin reuptake inhibitors (SSRIs) are a first-
line treatment option (Kemp et al., 2008) for both mood and
anxiety disorders and admixtures of the two, and are also used
widely in bipolar depression (Malhi, 2012). SSRIS have important
acute neurophysiological effects (Kemp and Nathan, 2004; Kemp
et al., 2004) providing the foundation upon which subsequent
therapeutic response is based (Harmer et al., 2009). Acute effects
are often studied in healthy samples to avoid confounds of illness
and psychopathology (Harmer, 2010). Interestingly, acute SSRI
treatment has been shown to attenuate cardiovascular responses
to stress (Straneva-Meuse, 2004a; Golding et al., 2005; Jiang et al.,
2013), However, longitudinal research indicates that they may
also have adverse cardiovascular effects, including reductions in
vagally mediated cardiovascular function (Licht et al., 2010b)
and sudden cardiac death (Whang et al., 2009), highlighting the
importance of research on antidepressant actions and the mod-
erating effects of specific lifestyle factors such as physical activity.
Physical activity is associated with improved psychological health
(Powell et al., 2011; Åberg et al., 2013) and lower cardiovas-
cular (and proinflammatory) responses to stress (Hamer and
Steptoe, 2007) lowering the risk of future CVD (Mora et al.,
2007; Hamer and Stamatakis, 2009; Hamer et al., 2009) and mor-
tality (Leitzmann et al., 2007). The higher the parasympathetic
activity at rest—indicated by lower HR and higher HRV—the
more autonomic resources available to tackle subsequent stres-
sors; a proposal known as the “autonomic resource hypothesis”
(Hynynen et al., 2008; Boullosa et al., 2012). Thus, research on the
impact of antidepressants and the moderating effects of physical
activity has important implications for not only better under-
standing therapeutic response to antidepressant medications, but
also for the long-term health of the cardiovascular system. Recent
research in outpatients with coronary heart disease and depres-
sion (Blumenthal et al., 2012) demonstrates that exercise and
sertraline (a SSRI) are equally effective at reducing depressive
symptoms after 16 weeks of treatment, but that exercise led to
greater improvements in HRV collected using 24-h Holter record-
ings compared with sertraline. However, it remains unclear, to
what extent physical activity and SSRIs interact in moderating the
effects of SSRIs on psychological stress.
Here we report on a proof-of-concept, laboratory-based,
experimental study to examine the acute effects of a commonly
prescribed SSRI, escitalopram, on HR and its variability under
stress, with the aim of determining whether individual differ-
ences in levels of physical activity moderate these effects. Better
understanding the impact of the SSRIs and the moderating effects
that specific lifestyle factors exert has important implications for
therapeutic responsiveness, psychological wellbeing, and physical
health. We focus specifically on acute treatment effects in healthy
female volunteers. We hypothesized that acute administration of
escitalopram would attenuate increases in HR and decreases in
HRV during stress, relative to placebo, and that regular vigorous
exercise would facilitate this effect.
METHODS
PARTICIPANTS
Forty-four healthy female volunteers (aged 18–47, M = 23.70,
SD = 5.89) completed the study, and gave written informed
consent in accordance with National Health Medical Research
Council guidelines. Participants were recruited using university-
wide staff and student newsletters. Participants were free from
medication (other than hormonal contraceptives), physical and
psychiatric illness, symptoms of depression and anxiety [PHQ-9
(Kroenke et al., 2001) and GAD-7 (Spitzer et al., 2006) assess-
ment], illicit drug use, alcoholism, smoking, brain injury, neu-
rological disorders, and sustained loss of consciousness. Only
female participants were recruited for this study as females dis-
play higher rates of mental disorders (Nolen-Hoeksema, 2001;
Kessler, 2003; Slade et al., 2009); focusing on females also
allowed us to avoid known gender differences in baseline HRV
(Rajendra Acharya et al., 2006), HRV responses to cognitive stress
(Li et al., 2009), and responsiveness to SSRI treatment (Khan
et al., 2005). Finally, participants abstained from caffeine on
the morning of the experiment and no participant tested posi-
tive on pregnancy tests, which were conducted at each session.
Ethics approval for the trial was secured from the University of
Sydney’s Human Research Ethics Committee (ref. 13901) and
the Northern Sydney Central Coast Area Health Service Human
Research Ethics Committee (ref. 1105-178M), and it was regis-
tered with the Australian New Zealand Clinical Trials Registry
(ANZCTR; ACTRN126111000719932).
EXPERIMENTAL DESIGN
Participants were randomly assigned to receive escitalopram
(20mg) or placebo per os, tested in a double-blind crossover
design, with two sessions per participant separated by at least 1
week to ensure a sufficient drug washout of at least 5 half-lives
(t1/2 = 26.7 h; Sogaard, 2005). Forty-five percent of participants
received placebo at the first session. Relative to other commonly
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prescribed SSRIs, escitalopram has improved efficacy, a lower
side effect profile, and greater selectivity for serotonergic trans-
port proteins (Fernandez et al., 2007; Cipriani et al., 2009a). The
maximum recommended dosage of 20mg was used to maxi-
mize receptor occupancy (Kasper et al., 2009) and subsequent
physiological effects from a single dose.
MEASUREMENT OF PHYSICAL ACTIVITY
Participants reported the frequency in which they engaged
in vigorous physical activity using the International Physical
Activity Questionnaire (IPAQ; Craig et al., 2003), a widely
used, reliable and valid self-report assessment. Physical activ-
ity data is transformed into energy expenditure estimates
of metabolic equivalent tasks (MET), such that one MET is
equivalent to the energy cost of sitting quietly for an hour
(1 kcal/kg/h). Participants were categorized into low or high
vigorous activity groups—according to national guidelines
(Australian Government Department of Health and Ageing:
http://www.health.gov.au/internet/main/publishing.nsf/content/
health-pubhlth-strateg-phys-act-guidelines). These guidelines
recommend at least 30min of vigorous physical activity 3 days
a week on top of regular moderate-intensity activity for health
and fitness benefits. Participants categorized in the low activity
grouping did not meet the criteria of at least 30min of vigorous
physical activity 3 days a week, while participants in the high
activity grouping met or exceeded this criterion. Groups did not
differ on time spent sitting, walking or performing moderate
physical activity (all p > 0.1). Groups were compared on resting
state HR, providing a (partial) validation of questionnaire-based
categorization (see participant characteristics).
STRESS MANIPULATION
The mental arithmetic task component of the Trier Social
Stress Test (TSST; Kirschbaum et al., 1993) was used to elicit
stress (Jönsson et al., 2010) and associated physiological corre-
lates, including HR, blood pressure, catecholamines and corti-
sol (Straneva-Meuse, 2004a; Vermetten, 2006). Participants were
instructed to count backwards subtracting thirteens, beginning
at either 2083 or 2027 for 5-min. Participants were given one of
these two alternate versions of the arithmetic task across sessions.
No feedback was given for correct responses, and the experi-
menter vocalized the word “error” when a mistake was made,
instructing the participant to start counting from the beginning,
further increasing stress and social pressure as per prior studies
(Hjortskov et al., 2004).
PROCEDURE
Testing was conducted in a psychophysiology laboratory at the
Clinical Assessment and Diagnostic Evaluation (CADE) Clinic
(www.cadeclinic.com), Royal North Shore Hospital. Participants
arrived in the early morning, having consumed breakfast, and
abstained from caffeine, as caffeine increases sympathetic nervous
system (SNS) activity (Sondermeijer et al., 2002). Participants
completed a consent form and pregnancy test. Height and weight
were measured at the first session to calculate BMI. Testing com-
menced 3 h after administration of either placebo or 20mg of
escitalopram, so as to coincide with the time of the expected peak
plasma concentration (Tmax = 3.0± 1.5 h; Sogaard, 2005; Rao,
2007) During the waiting period, the participant was provided
with a standardized snack and in the first session only, completed
the IPAQ. The snack helped to minimize autonomic and mood
changes associated with hunger. In order to determine the pres-
ence of side effects, subjective wellness was recorded during the
waiting period and after psychophysiological testing. Participants
reported whether they experienced side effects and were asked to
guess their treatment condition in order to examine the potential
impact of treatment unblinding at each session.
All participants were tested in the late morning, and at the
same time on each session to control for potential changes in
HRV with circadian rhythms (Kleiger et al., 2005). Participants
sat in a reclined chair with their legs raised and were instructed
to breathe normally, remain still and awake for 5-min of data
collection in the resting state. Following this, 5-min recordings
were made during the stress condition in which participants were
required to perform themental arithmetic task. The experimenter
was seated in close proximity to the participant and acted in a for-
mal manner, in order to further increase the stressful nature of the
procedure through social pressure (Hjortskov et al., 2004). After
testing, subjective ratings of relaxation and stress for each condi-
tion were recorded on a five-point Likert scale (from low to high)
to determine the efficacy of the experimental manipulations.
Participants provided saliva samples (1mL) for estradiol and
progesterone analysis before treatment administration at each
session. The hormonal saliva samples were stored frozen until
assay. On the day of assay, samples were thawed for determina-
tion of salivary progesterone and estradiol using commercially
available kits (Salimetrics, USA) according to the manufactur-
ers instructions. Thawed samples were centrifuged at 1500 × g
for 15min to collect clear saliva which was used without fur-
ther processing for all assays. All samples were brought to room
temperature before adding to assay wells and all samples were
analyzed in duplicate. Hormonal menstrual phase was deter-
mined in accordance with previous research (Lu et al., 1999;
Gandara et al., 2007).
DATA COLLECTION AND ANALYSIS
HR and R-R interval recordings—on which analyses of HRV
were conducted—were made during two conditions, consistent
with Task Force guidelines (Task Force of the European Society
of Cardiology and the North American Society of Pacing and
Electrophysiology, 1996): (1) a 5-min resting state and (2) a
5-min social stress task, using a Polar RS800CX training device
at a sampling rate of 1000Hz. These devices have been validated
against the electrocardiogram (ECG) and have excellent reliabil-
ity, especially in young, healthy individuals in a supine position
and when analysis is conducted on normalized values (Gamelin
et al., 2006; Weippert et al., 2010) (see also Quintana et al., 2012),
as was the case in the current study. This device is wirelessly con-
nected to an electrode strap worn just beneath the chest, that has
been wetted with saline solution (0.9% NaCl) to simulate sweat
and ensure conductivity. R-R intervals were extracted from text
files and analyzed in Kubios HRV analysis software (version 2.0,
2008, biosignal analysis and medical imaging group, University of
Kuopio, Finland, MATLAB). Each file was visually inspected for
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artifacts (ectopic and missing beats), and medium automatic fil-
ter corrections were applied to each data set. Measures of HRV
included HF HRV (normalized units, n.u.) (0.15–0.40Hz) and
the Root Mean Square of the Successive Differences (RMSSD).
STATISTICAL ANALYSIS
All statistical analyses were conducted using IBM SPSS Statistics
(Version 20) for Windows 7. The impact of escitalopram and
the moderating effects of physical activity levels on HR and
heart rate variability (HRV) were examined using mixed within-
and between-subjects analysis of variance (ANOVA). Within
subject factors were treatment (escitalopram vs. placebo) and
task (stress vs. rest) and the between subjects factor was phys-
ical activity (high vs. low). A factor of “treatment order” was
not included in statistical analysis for parsimony; order effects
are rare, are generally underpowered even when an apprecia-
ble effect is present, and sufficient drug washout ameliorates
such concerns (Senn, 1994; Senn et al., 2004; Mills et al.,
2009). Independent samples t-tests were conducted to deter-
mine whether low and high activity groupings differed across
demographic variables (Table 1). ANOVA was also employed to
determine whether subjective ratings of relaxation and stress dif-
fered across treatment sessions and physical activity groupings.
Cohen’s d effect size statistics were calculated for each pair-
wise comparison. Cohen’s guidelines (Cohen, 1988a,b) identify
0.2, 0.5, and 0.8 as small, medium, and large effects, respec-
tively. Partial eta-squared (η2p) was reported for ANOVA effects
as an indicator of effect size (small = 0.01 medium = 0.06,
large = 0.14; (Cohen, 1988a,b). The statistical threshold of 0.05
(two-tailed) was set for all analyses, except where directional
effects were expected, in which one-tailed tests were employed.
Manipulation checks included a focus on whether hormone or
menstrual status, or treatment blinding differentially impacted
on the results reported below. With respects to hormone and
menstrual status, χ2 tests were conducted to check for equal pro-
portions of participantmenstrual phase within treatment sessions
and equal proportions of participants using hormonal contra-
ceptives in each order of treatment. Regression analyses were
also conducted on hormone concentrations in order to deter-
mine the relationships between hormone levels and the HR and
HRV responses under each treatment and task condition. With
respects to treatment blinding, χ2 tests were performed to exam-
ine the relationship between guessing treatment condition and
experiencing side effects. The effect of guessing and side effects
on HR and HRV under each treatment and task condition was
determined using repeated-measures ANOVAs on HR and HRV
separately.
RESULTS
PARTICIPANT CHARACTERISTICS
Participant characteristics are presented in Table 1 and flow of
participants through the different stages of the study is presented
in Figure 1. The two physical activity groupings were matched
in terms of age, BMI, years of education, time spent sitting,
walking or performing moderate physical activity (all p > 0.1).
The high activity group spent more minutes in the past week in
vigorous activity [t(38) = 6.93, p < 0.001, d = 2.26], and had a
higher weekly energy expenditure [t(38) = 3.50, p = 0.001, d =
1.12] relative to the low activity group. Regardless of treatment,
resting HR was significantly lower in the high activity group in
comparison to the low activity group [t(38) = 1.71, p = 0.048
(one-tailed), d = 0.55], suggesting cardiovascular adaptations in
the high activity group that may be explained by the link between
bradycardia, regular exercise and physical fitness. Four partic-
ipants were identified as multivariate outliers on HR variables
using Tabachnick and Fidell’s (2007) multivariate outliers identi-
fication procedure, and were subsequently excluded from further
analysis. Forty participants aged between 18 and 47 (M = 23.70,
SD = 5.89) were included in final analyses.
HORMONAL RESULTS
The χ2 tests demonstrated that participants were equally dis-
tributed between menstrual phases on placebo, χ2(2) = 0.950,
p = 0.622, and escitalopram, χ2(2) = 0.950, p = 0.622, treatment
sessions. There was an equal distribution of participants who took
hormonal contraceptives to those who did not, χ2(2) = 0.100,
p = 0.752 and hormonal contraceptive status was equally dis-
tributed between those who received placebo or escitalopram at
their first session, χ2(1) = 0.002, p = 0.962. Regression analyses
on HR and HRV data for each task and treatment condition
showed no significant associations with progesterone or estradiol
concentration [all p > 0.05 (Bonferroni corrected for multiple
analyses)]. Additionally, there were no differences between those
who did and did not take hormonal contraceptives on each task
and treatment condition [HR, F(1, 38) = 0.544, p = 0.465; HRV,
F(2, 37) = 0.733, p = 0.487].
TREATMENT BLINDING MANIPULATION CHECK
A greater proportion of participants (70%) were found to cor-
rectly guess treatment condition than that which was expected
by chance, χ2(1) = 6.400, p = 0.011. Side effects also occurred in
48% of the sample, although these did not occur in a greater pro-
portion than that expected by chance, χ2(1) = 0.100, p = 0.752.
There was, however, a significant association between the sub-
jective experience of side effects and correct treatment guessing,
χ2(1) = 6.535, p = 0.011, indicating that participants who cor-
rectly guessed treatment condition were likely to have made this
correct guess based on their experience of side effects. Repeated-
measures ANOVAs testing the interaction between presence of
side effects and correct guessing of treatment were performed on
the HR and HF HRV measures. Importantly, no significant inter-
action effects of correct guessing× side effects× treatment× task
on HR [F(1, 36) = 0.428, p = 0.517] or HRV [F(1, 35) = 0.995,
p = 0.380] were observed.
SUBJECTIVE RATINGS OF TASK
A significant interaction between task and physical activity
groupings on subjective ratings was observed, [F(1, 32) = 7.17,
p = 0.012, η2p = 0.18]. Follow-up pairwise comparisons demon-
strated that participants in the high physical activity group
reported significantly lower mental stress during the stress task,
than the low physical activity group, t(32) = 2.84, p = 0.008,
d = 1.00. Therefore, the less physically active group found the
mental stress task more stressful than the more physically active
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Table 1 | Participant demographic information.
Low PA (n = 18) High PA (n = 22) Statistics
Mean SD Mean SD
Age (years) 24.06 7.78 23.41 3.91 t(38) = 0.34,
p = 0.735
Education (years) 16.11 2.76 16.77 2.83 t(38) = −0.74,
p = 0.462
Ethnicity (C/NC) 1/17 1/21 χ2
(1) = 0.021,
p = 0.884
BMI (kg/m2) 21.88 2.60 23.40 3.30 t(38) = −1.58,
p = 0.122
Hormonal contraceptive use (Y/N) 9/9 12/10 χ2
(1) = 0.082,
p = 0.775
Menstrual phase placebo (F/M/L) 8/5/5 8/6/8 χ2
(2) = 0.387,
p = 0.824
Menstrual phase drug (F/M/L) 6/5/7 10/8/4 χ2
(2) = 2.132,
p = 0.344
Side effects (Y/N) 8/10 11/11 χ2
(1) = 0.123,
p = 0.726
Correct treatment guess (Y/N) 14/4 14/8 χ2
(1) = 0.943,
p = 0.332
AUDIT total (SD) 6.11 (4.13) 6.45 (5.32) t(38) = −0.224,
p = 0.824
Smoking (Y/N) 0/18 0/22 n/a
PHQ-9 (SD) 1.61 (1.20) 1.45 (1.22) t(38) = 0.407,
p = 0.686
GAD-7 (SD) 0.72 (0.895) 1.41 (1.26) t(38) = −1.945,
p = 0.059
IPAQ (mins/wk)
Vigorous intensity activity 30.28 58.37 207.05 94.30 t(38) = −6.93,
p < 0.001 (one-tailed),
d = 2.26
Moderate intensity activity 206.11 230.12 278.41 222.43 t(38) = −1.01,
p = 0.320
Walking 461.94 297.85 457.50 284.12 t(38) = 0.05,
p = 0.962
Sitting 366.67 180.75 351.82 153.30 t(38) = 0.28,
p = 0.780
Total physical activity 698.33 428.23 942.94 408.14 t(38) = −1.85,
p = 0.073
Energy expenditure, METs-min/week 2620.53 1650.94 4546.11 1793.27 t(38) = −3.50,
p = 0.001,
d = 1.12
Resting HR 71.78 8.56 66.14 14.10 t(38) = 1.71,
p = 0.048
(one-tailed),
d = 0.55
Abbreviations: PA, physical activity; BMI, body mass index; PHQ-9, patient health questionnaire; GAD-7, generalised anxiety disorder screener; IPAQ, international
physical activity questionnaire; MET, metabolic equivalent task.
group, regardless of treatment. Importantly, however, a main
effect of task was also observed indicating that participants were
more stressed in the arithmetic task than during the rest condition
[F(1, 32) = 102.77, p < 0.001, η2p = 0.76], confirming the valid-
ity of the stress condition in our sample, regardless of physical
activity groupings. No main effects of physical activity [F(1, 32) =
2.49, p = 0.124] or treatment [F(1, 32) = 2.35, p = 0.135], or
interactions between treatment and task [F(1, 32) = 2.26, p =
0.142] or treatment, task, and physical activity [F(1, 32) = 0.228,
p = 0.637] were observed on subjective ratings.
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FIGURE 1 | A depiction of participants’ attrition from the experiment and the reasons and stages at which they were excluded.
IMPACT OF ESCITALOPRAM AND THE MODERATING EFFECTS OF
PHYSICAL ACTIVITY
Descriptive statistics for HR and HRV in high and low activity
groupings for task and treatment are presented in Figure 2 and
Table 2.
Heart rate
A three-way interaction between treatment, task and activity level
was significant, [F(1, 38) = 7.18, p = 0.011 η2p = 0.16]. Relative
to placebo, escitalopram reduced HR in both the low activ-
ity [t(38) = 2.80, p = 0.008, d = 0.45] and high activity [t(38) =
2.24, p = 0.031, d = 0.36] groups during rest. Escitalopram also
reduced HR in the low activity group [t(38) = 4.97, p < 0.001,
d = 0.80] during stress. By contrast, escitalopram did not reduce
HR in the high activity group during stress (Figure 2). Notably,
HR for the high activity group during stress under placebo, was
markedly reduced relative to those in the low activity group
[t(38) = 2.13, p = 0.040, d = 0.48], and equivalent to HR for the
low activity group under drug (Figure 2), indicating that those
in the high activity group display a more resilient cardiovascu-
lar response to stress than those in the low activity group. This
interpretation is further supported by the observation of an inter-
action between task and physical activity grouping on subjective
ratings of task (reported above). These findings were observed
on a background of a significant treatment × task interaction
[F(1, 38) = 6.61, p = 0.014, η2p = 0.15], a main effect of treatment
[F(1, 38) = 22.18, p < 0.001, η2p = 0.37], and a main effect of task
[F(1, 38) = 210.43, p < 0.001, η2p = 0.85] collapsed across physi-
cal activity groupings. These findings indicate that the increase in
HR under stress (relative to rest) was decreased by escitalopram
(a treatment × task interaction), that HR was decreased by esci-
talopram (a main effect of treatment) and that HR was increased
under stress (a main effect of task).
Heart rate variability
No significant three-way interaction was found for HRV
[F(2, 37) = 0.23, p = 0.80]. Univariate tests for the three-way
interaction between treatment, task and vigorous activity were
not significant for HF F(1, 38) = 0.06, p = 0.804, or RMSSD,
F(1, 38) = 0.47, p = 0.496. However, a main effect of task was
observed indicating that HRV was decreased by stress, relative
to the rest, regardless of treatment [RMSSD, F(1, 38) = 35.99,
p < 0.001, d = 0.96; and HF, F(1, 38) = 84.60, p < 0.001, d =
1.47]. Interestingly, post-hoc, pairwise comparisons indicated that
escitalopram—relative to placebo—increased RMSSD (but not
HF) during stress in the low activity group [t(37) = 2.07, p =
0.046, d = 0.33], mirroring the findings of HR. No other pairwise
comparisons were significant.
DISCUSSION
Recent reports on the adverse cardiovascular effects of the second-
generation antidepressants (Whang et al., 2009; Licht et al.,
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FIGURE 2 | The interaction between treatment and physical
activity category on cardiovascular responses (with standard
error bars). Top left graph: Effects on HR at rest. Top right
graph: effects on RMSSD at rest. Lower left graph: Effects on
HR during stress. Lower right graph: effects on RMSSD during
stress.
Table 2 | HR and RMSSD means and standard deviations for vigorous exercise groups under each treatment for rest and stress conditions.
Low vigorous activity % High vigorous activity %
PlaceboM (SD) DrugM (SD) PlaceboM (SD) DrugM (SD)
HR Rest 74.13 (8.56) 69.43 (6.93) −6.3 67.84 (14.10) 64.45 (11.83) −5
Stress 94.80 (10.45) 84.12 (10.03) −11.2 84.62 (17.93) 81.34 (15.21) −3.9
% 27.9 21.2 24.7 26.2
RMSSD Rest 49.03 (24.80) 48.79 (23.77) −0.4 61.22 (37.45) 59.27 (31.41) −3.2
Stress 31.27 (14.18) 38.25 (18.17) 22.3 42.94 (32.81) 43.13 (33.45) 0.4
% −36.2 −21.6 −29.9 −27.2
2010a), highlight the importance of research on specific lifestyle
factors such as physical activity. Major findings observed here
were that (a) participants in the high physical activity group (reg-
ular vigorous exercisers) reported feeling less stressed than those
in the low physical activity grouping (irregular exercisers) dur-
ing the stress task (i.e., an interaction between task and physical
activity groupings on subjective ratings on task); this finding
was associated with a large effect size (Cohen’s d = 1.00), (b) all
participants reported feeling more stressed in the stress vs. rest
condition (i.e., a main effect of task), a finding associated with a
large effect size (η2p = 0.76), providing an important validation of
our task in the context of an interaction between group and physi-
cal activity grouping, (c) irregular—relative to regular—exercisers
display attenuated cardiovascular responses to stress following
treatment with escitalopram (i.e., a three-way interaction between
treatment, task and activity for HR, also indicated in a post-
hoc test on HRV), a finding associated with a moderate to large
effect size (HR: Cohen’s d = 0.80; RMSSD HRV: Cohen’s d =
0.33), and (d) regular—relative to irregular—exercisers displayed
a markedly lower HR under placebo (i.e., a three-way interaction
between treatment, task and activity for HR), a finding associated
with a moderate effect size (Cohen’s d = 0.48).
We show here that irregular exercisers—those participants that
did not engage in 30min of vigorous physical activity at least 3
days a week—reported feeling more stressed after the stress task
and following an acute dose of escitalopram treatment, they dis-
played improvements in vagally mediated cardiovascular function
during stress. Importantly, these subjective and objective find-
ings relating to the impact of acutely administered escitalopram
during stress were also observed regardless of physical activity
grouping. The interactions with physical activity simply highlight
that the beneficial effects of escitalopram were greatest in irreg-
ular exercisers. This effect was most prominent for HR, but was
also observed in planned comparisons for HR variability. The
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impact of escitalopram on HRV under stress was not as robust
as the observed findings for HR, however, this observation is
understandable because under conditions of stress, parasympa-
thetic activity, which is the primary driver of changes in HRV, is
withdrawn and this reduces the capacity of other factors to mod-
erate reductions in HRV during stress (observed as a main effect
of task).
While animal and human studies (Babyak et al., 2000;
Engesser-Cesar et al., 2007; Arunrut et al., 2009) have indi-
cated that the combination of exercise and antidepressant med-
ication may confer no advantage over either treatment alone,
there is another issue at stake here. Although antidepressant
medication—including the tricyclic medications, the serotonin
and noradrenaline reuptake inhibitor and the selective serotonin
reuptake inhibitors—may have short- to medium-term benefits
including the amelioration of depressive symptoms and increased
resilience to stress, research has begun to highlight the longer-
term adverse cardiovascular effects of antidepressants (Whang
et al., 2009; Licht et al., 2010a). Reductions in HRV have been
attributable to the specific effects of antidepressants (Licht et al.,
2008, 2010a) while increases in HRV are associated with their
cessation (Licht et al., 2010a). An epidemiological study (Whang
et al., 2009) on 63,469 women aged 30–55 years without base-
line coronary heart disease (CHD) reported that while depressive
symptoms were associated with fatal CHD, antidepressant use
(61% of participants were using an SSRI) was specifically associ-
ated with a 3.34 increased risk for sudden cardiac death even after
controlling for a variety of confounds. A more recent study has
reported that reduced cardiovascular fitness is associated with an
increased risk of suicide over a 42 year follow-up period (Åberg
et al., 2013) highlighting the importance of cardiovascular health
over the lifespan. Together, these findings highlight the impor-
tance of research on the cardiovascular effects of antidepressants
and specific lifestyle factors such as physical activity. The present
study makes an important contribution to this effort highlighting
that the cardiovascular effects of regular vigorous exercise and of
an acute dose of escitalopram during stress are comparable, i.e.,
both are associated with a decrease in HR and an increase in HRV.
Here we propose a simplified model for the beneficial effects
of regular vigorous physical activity and SSRI treatment on vagal
tone, initiating a path toward mental and physical wellbeing (see
Figure 3). Increased vagal function is associated with increased
psychophysiological flexibility (Thayer et al., 2009; Kashdan and
Rottenberg, 2010) and stress resilience, which in turn promotes
wellbeing (Oveis et al., 2009; Geisler et al., 2010, 2013; Kashdan
and Rottenberg, 2010; Kok and Fredrickson, 2010; Thayer et al.,
2010b; Kemp and Quintana, 2013). Increased vagal function
also initiates downstream neurophysiological changes such as
enhanced growth factors (Follesa et al., 2007), improved regula-
tion of HPA axis function and inflammatory processes (Tracey,
2002; Thayer and Sternberg, 2006; Huston and Tracey, 2010;
Pavlov and Tracey, 2012), leading to improved wellbeing (Thayer
et al., 2010b; Kemp and Quintana, 2013). The model also high-
lights the direct links between regular vigorous physical activity
and wellbeing (discussed above). However, it is noted that over-
trained athletes also display a decease in HRV, which limits
the autonomic resources available to respond to emotional and
physical stress (Hynynen et al., 2008; Boullosa et al., 2012).
FIGURE 3 | A simplified model for the beneficial effects of regular
vigorous physical activity and SSRI treatment on vagal tone, initiating
a path towards mental and physical wellbeing.
In the present study we demonstrated that acute adminis-
tration of escitalopram is associated with increased vagal func-
tion under both resting and task conditions; a finding that
was particularly robust for HR. This finding is consistent with
reported short- to medium-term beneficial effects of SSRIs
on cardiovascular and neuroendocrine responses to stress in
depressed patients (e.g., Straneva-Meuse, 2004b), but contrast
against longer-term research outcomes (Whang et al., 2009; Licht
et al., 2010a) highlighting the adverse effects of the SSRI class of
antidepressants. Here, an explanation for this apparent discrep-
ancy is the complexity of central and autonomic 5-HT effects
on cardiovascular function, which include bradycardia, associ-
ated with activation of 5-HT1A receptors, as well as tachycardia,
associated with activation of 5HT2 receptors. It is possible that
the effects of SSRIs shift from parasympathetic—as shown here—
to sympathetic activation with increasing length of use. Further
research is urgently needed on the combination of antidepressants
and physical activity over longer-time frames than typical clinical
trials (i.e., years rather than months).
A number of limitations are worth noting. Participants cor-
rectly guessed treatment condition beyond chance due to side
effects, consistent with those typically experienced with escitalo-
pram (Cipriani et al., 2009b). However, neither experience of side
effects, nor accuracy of treatment guess impacted on HR or HRV.
Experimenters were also blinded to individual participants’ phys-
ical activity levels and participants were not aware that physical
activity was of primary interest. It is therefore unlikely that the
experience of side effects and correctly guessing treatment would
have confounded the obtained findings. Another limitation is the
use of a questionnaire based-measure of physical activity. It is
possible that our measure reflects recent regular physical activ-
ity, rather than fitness per se. Future studies could consider use of
objective measures of fitness such as VO2 max to confirm that
those engaging in regular activity are indeed characterized by
higher levels of fitness. Future studies with clinical samples and
chronic treatment are also needed to further examine the util-
ity of combining antidepressantmedication and vigorous physical
activity.
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In summary, results from this experimental study highlight
the adverse impact of stress on vagally mediated cardiovascular
function and the beneficial moderating effects of escitalopram
as well as regular vigorous physical exercise. Escitalopram was
observed to increase vagal function under both rest and stress
conditions, and under stress, these effects are specific to irregu-
lar exercisers, but not regular exercisers. We propose a simplified
model for understanding the beneficial effects of physical activity
and antidepressants on cardiovascular function that may subse-
quently lead to improved mental and physical activity. Our study
and model provide a foundation on which future research could
be based. Increasing concerns about the bidirectional relation-
ship between depression and CVD, reinforce the need for further
research on the impact of antidepressants, physical activity and
their combination, that is not only focused on amelioration of
depressive symptoms, but also on vagally mediated cardiovascular
function.
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